Announcements Trials
Browse Landscape

Phase

Phase 2 37Phase 1 36Phase 1/2 24Phase 3 11Phase 2/3 2Phase 4 1

Status

Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Neoplasms 22Breast Neoplasms 20Neoplasm Metastasis 18Colorectal Neoplasms 16Stomach Neoplasms 15Recurrence 15Prostatic Neoplasms 15Carcinoma, Hepatocellular 12Pancreatic Neoplasms 11Ovarian Neoplasms 11Head and Neck Neoplasms 11Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 10Leukemia, Myeloid, Acute 10Myasthenia Gravis 9Melanoma 9Urinary Bladder Neoplasms 8Lymphoma, Large B-Cell, Diffuse 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Liver Neoplasms 6Cholangiocarcinoma 6Carcinoma, Transitional Cell 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Lymphoma, Follicular 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia 5

Interventions

4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × Lymphoma, T-Cell, Peripheral × Clear all
NCT06548347 2024-08-12

A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma

Shanghai YingLi Pharmaceutical Co. Ltd.

Phase 2/3 Not yet recruiting
606 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04021082 2023-02-21

CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

Alexion Pharmaceuticals, Inc.

Phase 2/3 Withdrawn
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, T-Cell, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡